Shares of Masimo MASI were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share rose 5.26% over the past year to $0.80, which beat the estimate of $0.62.
Revenue of $278,112,000 higher by 21.44% year over year, which beat the estimate of $256,580,000.
Looking Ahead
Masimo Sees FY20 Adj. EPS $3.46 vs $3.17 Estimate, Sales $1.128B vs $1.09B Est.
Details Of The Call
Date: Oct 27, 2020
Time: 04:30 PM
Recent Stock Performance
Company's 52-week high was at $258.00
Company's 52-week low was at $140.53
Price action over last quarter: Up 14.66%
Company Description
Masimo is an Irvine, California-based medical device business that focuses on noninvasive patient monitoring. It began by developing superior signal processing algorithms to measure blood oxygenation levels through pulse oximetry and has expanded this expertise into a wide range of measurements and applications. The company generates revenue globally, with the United States the largest market (68% of 2019 sales), followed by Europe, the Middle East, and Africa (20%), Asia and Australia (9%), and North and South America excluding the U.S. (3%).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.